Medicines Co. (MDCO): Positive ORION-1 Data Could Bring 2-3x Per Year Dosing - Jefferies

November 16, 2016 7:14 AM EST
Get Alerts MDCO Hot Sheet
Price: $34.85 +6.19%

Rating Summary:
    15 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade MDCO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of The Medicines Company (NASDAQ: MDCO) after the company detailed positive PIIb ORION-1 data investigating inclisiran for hypercholesterolemia at AHA. The analyst stated "Inclisiran at 300 mg demonstrated a mean ~50% LDLC reduction at 3 mo, and a second dose at 3 mo drove LDL reduction close to ~60%. Going forward MDCO believes the dosing freq will be no more than 2-3x per year (bi-/triannual dosing), which we believe is differentiated compared to Repatha and Praluent".

No change to the price target of $43.

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.

Shares of The Medicines Company closed at $36.79 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment